BiomX Inc. (NYSE:PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today
Companies Reporting Before The Bell
• Genetron Holdings (NASDAQ:GTH) is expected to report quarterly loss at $0.18 per share on revenue of $14.21 million.